The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | Combining ADCs with other treatment modalities in NSCLC
Benjamin Besse, MD, PhD, Gustave Roussy, Villejuif, France, discusses the potential of combining antibody-drug conjugates (ADCs) with other available therapies such as standard platinum-based chemotherapies and immunotherapies for the treatment of non-small cell lung cancer (NSCLC). Dr Besse delves into the toxicities typically associated with ADCs, and the potential synergistic toxicities that may be present when combining with other treatment modalities. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
